Editorial: De-risking novel therapeutic development |[ndash]| time to stop blaming the molecule?

Journal of Commercial Biotechnology (2005) 12, 5–7; doi:10.1057/palgrave.jcb.3040142

Editorial: De-risking novel therapeutic development – time to stop blaming the molecule?

Simon Shohet

Healthcare and Life Science Consulting, Cambridge Consultants Ltd, UK

Previous | Next

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.